These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35754404)

  • 1. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
    Liu R; Qiu K; Wu J; Jiang Y; Wu P; Pang J
    Immunotherapy; 2022 Aug; 14(11):859-869. PubMed ID: 35754404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
    Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
    Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
    Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
    Front Public Health; 2022; 10():954264. PubMed ID: 36159269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
    Markham A
    Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
    Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
    Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
    Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Pharmacol; 2021; 12():736860. PubMed ID: 34966275
    [No Abstract]   [Full Text] [Related]  

  • 9. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
    Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
    Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Burotto M; Escudier B; Bourlon MT; Zurawski B; Oyervides Juárez VM; Hsieh JJ; Basso U; Shah AY; Suárez C; Hamzaj A; Goh JC; Barrios C; Richardet M; Porta C; Kowalyszyn R; Feregrino JP; Żołnierek J; Pook D; Kessler ER; Tomita Y; Mizuno R; Bedke J; Zhang J; Maurer MA; Simsek B; Ejzykowicz F; Schwab GM; Apolo AB; Motzer RJ;
    N Engl J Med; 2021 Mar; 384(9):829-841. PubMed ID: 33657295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
    Wan X; Zhang Y; Tan C; Zeng X; Peng L
    JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
    Wu B; Zhang Q; Sun J
    J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma.
    Liu T; Jin Y; Dong M
    Clin Genitourin Cancer; 2023 Dec; 21(6):e449-e460. PubMed ID: 37271697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
    Tran BD; Li J; Ly N; Faggioni R; Roskos L
    Cancer Chemother Pharmacol; 2023 Feb; 91(2):179-189. PubMed ID: 36625894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
    Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Huo S; Del Tejo V; Du EX; Yang X; Betts KA; Choueiri TK; McGregor B
    Clin Drug Investig; 2022 Jul; 42(7):611-622. PubMed ID: 35696045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
    Powles T; Burotto M; Escudier B; Apolo AB; Bourlon MT; Shah AY; Suárez C; Porta C; Barrios CH; Richardet M; Gurney H; Kessler ER; Tomita Y; Bedke J; George S; Scheffold C; Wang P; Fedorov V; Motzer RJ; Choueiri TK
    ESMO Open; 2024 May; 9(5):102994. PubMed ID: 38642472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
    Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.